Free shipping over €250 · Tracked, discreet delivery in Europe
UU library
Every peptide, mapped to the body.
160 compounds, from approved medicines to early research molecules. Each one filed by the system research looks at, with its regulatory status and the strength of the evidence behind it.
- Compounds
- 160
- Research summaries
- 39
- At UU
- 56
- Approved medicine71
Approved as a medicine by the FDA or the EMA for at least one indication. Approval covers the named indication and formulation only.
- In clinical trials19
In human clinical trials and not yet approved by the FDA or the EMA. Results to date are from trial populations under medical supervision.
- Research compound53
Not approved as a medicine by the FDA or the EMA. Some are registered in individual countries. Supplied for laboratory research only.
- Cosmetic ingredient17
Used as a topical cosmetic ingredient. Cosmetic use is not a medicinal approval, and most evidence comes from manufacturer and small panel studies.
Reviewed October 2026
In the UU catalog
Researched, batch-tested, ready to ship.
Compounds UU carries that have a full research summary in the library.
160 compounds
Brain, mood & sleep13
Peptides studied for cognition, stress response, sleep architecture and the nervous system.
- Research
Cerebrolysin
Porcine brain peptide mixture
A mixture of low-molecular-weight peptides from pig brain, registered in several European and Asian countries but not by the FDA or the EMA. Studied after stroke and brain injury.
Summary pending - Approved
Glatiramer acetate
Copaxone
Random amino acid copolymer
A mixture of polypeptides built from four amino acids. Approved for relapsing forms of multiple sclerosis.
Summary pending - In trials
NNZ-2591
Cyclic glycine-proline analogue
A synthetic analogue of a natural IGF-1 metabolite. In clinical trials for rare neurodevelopmental disorders.
Summary pending - Approved
Trofinetide
Daybue
IGF-1 tripeptide analogue
A synthetic analogue of the N-terminal tripeptide of IGF-1. Approved by the FDA in 2023 for Rett syndrome.
Summary pending - Approved
Ziconotide
Prialt
N-type calcium channel blocker
A synthetic form of a cone snail toxin. Approved for severe chronic pain, given into the spinal fluid.
Summary pending
Skin & hair22
Copper peptides, melanocortins and the signal peptides used in skin research and cosmetics.
- ApprovedAt UU
Afamelanotide
Melanotan I · Scenesse
Melanocortin agonist
A stabilised analogue of alpha-MSH. Approved as an implant for erythropoietic protoporphyria, a rare light-sensitivity disorder.
Human trialsShop - ResearchAt UU
Glutathione
L-glutathione · GSH
Antioxidant tripeptide
The main antioxidant tripeptide inside human cells. Studied in redox biology, liver research and skin pigmentation.
Early human dataShop - Cosmetic
Acetyl tetrapeptide-5
Eyeseryl
Cosmetic peptide
A tetrapeptide used in eye-area formulas. Studied in small panels for puffiness and skin elasticity.
Summary pending - Cosmetic
Argireline
Acetyl hexapeptide-8
SNARE-mimicking peptide
A hexapeptide modelled on part of the SNAP-25 protein. One of the most widely used cosmetic peptides for expression lines.
Summary pending - Cosmetic
Carnosine
Beta-alanyl-L-histidine
Dipeptide
A dipeptide concentrated in muscle and brain. Used in skincare and supplements, and studied for glycation and muscle buffering.
Summary pending - In trials
Dersimelagon
MT-7117
Oral MC1R agonist
An oral small-molecule MC1 receptor agonist. In clinical trials for erythropoietic protoporphyria.
Summary pending - Approved
Difelikefalin
Korsuva · Kapruvia
Peripheral kappa-opioid agonist
A peptide that acts on kappa-opioid receptors outside the brain. Approved for itch linked to chronic kidney disease on haemodialysis.
Summary pending - Cosmetic
Hexapeptide-9
Collagen-derived peptide
A peptide modelled on repeating sequences of collagen. Used in barrier and firmness formulas.
Summary pending - Cosmetic
Leuphasyl
Pentapeptide-18
Enkephalin-mimicking peptide
A pentapeptide studied in cosmetic panels alongside Argireline for expression lines.
Summary pending - Cosmetic
Matrixyl
Palmitoyl pentapeptide-4
Signal peptide
A lipid-linked fragment of type I procollagen. Studied in small cosmetic trials for fine lines and skin texture.
Summary pending - Research
Melanotan II
MT-II
Melanocortin agonist
A cyclic, non-selective melanocortin agonist never approved as a medicine. Studied for pigmentation, and the parent compound of bremelanotide.
Summary pending - Cosmetic
Nonapeptide-1
Melanostatine
MC1R antagonist
A nine-residue peptide that competes with alpha-MSH at the MC1 receptor. Used in cosmetic formulas for uneven pigmentation.
Summary pending - Cosmetic
Oligopeptide-1
sh-Oligopeptide-1 · EGF
Epidermal growth factor
A recombinant form of human epidermal growth factor. Used in cosmetic serums and studied in wound-healing research.
Summary pending - Cosmetic
Palmitoyl hexapeptide-12
Elastin-derived peptide
A lipid-linked repeat of an elastin sequence. Used in firmness formulas.
Summary pending - Cosmetic
Palmitoyl tetrapeptide-7
Signal peptide
A lipid-linked tetrapeptide studied in vitro for interleukin-6 signalling in skin cells. A common partner of palmitoyl tripeptide-1.
Summary pending - Cosmetic
Palmitoyl tripeptide-1
Pal-GHK
Signal peptide
A lipid-linked form of the GHK sequence. Used in collagen-focused cosmetic formulas, often paired with palmitoyl tetrapeptide-7.
Summary pending - Cosmetic
Palmitoyl tripeptide-38
Matrixyl synthe'6
Signal peptide
A lipid-linked tripeptide studied in manufacturer panels for extracellular matrix proteins and wrinkle depth.
Summary pending - Cosmetic
SYN-AKE
Dipeptide diaminobutyroyl benzylamide diacetate
Acetylcholine receptor antagonist
A small synthetic peptide modelled on a component of temple viper venom. Used in cosmetics for expression lines.
Summary pending - Cosmetic
Tripeptide-10 citrulline
Decorinyl
Decorin-mimicking peptide
A tetrapeptide designed to mimic part of decorin. Studied for collagen fibril organisation in skin.
Summary pending
Gut & weight38
Incretins, amylin analogues and gut peptides studied for appetite, glucose and body weight.
- In trialsAt UU
Cagrilintide
Long-acting amylin analogue
A weekly amylin analogue in clinical trials, alone and combined with semaglutide, for weight reduction.
Human trialsShop - ApprovedAt UU
Semaglutide
Ozempic · Wegovy
GLP-1 receptor agonist
A long-acting GLP-1 analogue approved for type 2 diabetes and chronic weight management, in weekly injected and daily oral forms.
Human trialsShop - ApprovedAt UU
Tesamorelin
Egrifta
GHRH analogue
A growth hormone-releasing hormone analogue approved to reduce excess abdominal fat in HIV-associated lipodystrophy.
Human trialsShop - ApprovedAt UU
Tirzepatide
Mounjaro · Zepbound
GIP and GLP-1 receptor agonist
A dual incretin agonist approved for type 2 diabetes and chronic weight management.
Human trialsShop - In trialsAt UU
Retatrutide
LY3437943
GIP, GLP-1 and glucagon receptor agonist
A triple-receptor agonist in Phase 3 trials. Studied for weight reduction, type 2 diabetes and liver fat.
Early human dataShop - ResearchAt UU
5-Amino-1MQ
NNMT inhibitor
A small molecule, not a peptide, that blocks the enzyme NNMT. Studied in rodents for fat mass and muscle ageing.
PreclinicalShop - ResearchAt UU
SLU-PP-332
ERR agonist
A small molecule that activates estrogen-related receptors. Studied in mice as an exercise mimetic.
PreclinicalShop - In trials
Amycretin
GLP-1 and amylin receptor agonist
A single molecule acting at both GLP-1 and amylin receptors. In clinical trials in oral and injected forms.
Summary pending - In trials
Apraglutide
Long-acting GLP-2 analogue
A weekly GLP-2 analogue in clinical trials for short bowel syndrome and intestinal graft-versus-host disease.
Summary pending - In trials
CagriSema
Amylin and GLP-1 combination
A fixed combination of cagrilintide and semaglutide in Phase 3 trials for obesity and type 2 diabetes.
Summary pending - Approved
Dasiglucagon
Zegalogue
Glucagon analogue
A stable, ready-to-use glucagon analogue approved by the FDA for severe hypoglycaemia.
Summary pending - Approved
Dulaglutide
Trulicity
GLP-1 receptor agonist
A weekly GLP-1 analogue fused to an antibody fragment. Approved for type 2 diabetes.
Summary pending - In trials
Efpeglenatide
GLP-1 receptor agonist
A long-acting GLP-1 agonist studied in cardiovascular outcome trials in type 2 diabetes.
Summary pending - Approved
Exenatide
Byetta · Bydureon
GLP-1 receptor agonist
The first GLP-1 agonist, based on a peptide from Gila monster saliva. Approved for type 2 diabetes.
Summary pending - In trials
Glepaglutide
Long-acting GLP-2 analogue
A long-acting GLP-2 analogue studied in Phase 3 trials for short bowel syndrome.
Summary pending - Approved
Glucagon
Pancreatic hormone
The pancreatic hormone that raises blood glucose. Approved for severe hypoglycaemia and as a diagnostic aid.
Summary pending - Research
HGH fragment 176-191
Growth hormone fragment
The unmodified C-terminal region of growth hormone that AOD-9604 is based on. Studied in animal models of fat metabolism.
Summary pending - Approved
Lanreotide
Somatuline
Somatostatin analogue
A long-acting somatostatin analogue approved for acromegaly and neuroendocrine tumours.
Summary pending - Approved
Linaclotide
Linzess · Constella
Guanylate cyclase-C agonist
An oral peptide that acts in the gut lining. Approved for irritable bowel syndrome with constipation.
Summary pending - Approved
Liraglutide
Victoza · Saxenda
GLP-1 receptor agonist
A daily GLP-1 analogue approved for type 2 diabetes and weight management.
Summary pending - Approved
Lixisenatide
Lyxumia
GLP-1 receptor agonist
A short-acting GLP-1 agonist approved for type 2 diabetes, also sold combined with insulin glargine.
Summary pending - In trials
Mazdutide
IBI362 · LY3305677
GLP-1 and glucagon receptor agonist
A dual agonist approved in China and in trials elsewhere. Studied for weight reduction and type 2 diabetes.
Summary pending - Approved
Octreotide
Sandostatin
Somatostatin analogue
A somatostatin analogue approved for acromegaly and symptoms of neuroendocrine tumours.
Summary pending - In trials
Pemvidutide
ALT-801
GLP-1 and glucagon receptor agonist
A dual agonist studied for obesity and liver fat in Phase 2 trials.
Summary pending - In trials
Petrelintide
Long-acting amylin analogue
A weekly amylin analogue in Phase 2 trials for weight management.
Summary pending - Approved
Plecanatide
Trulance
Guanylate cyclase-C agonist
An oral analogue of uroguanylin approved by the FDA for chronic constipation.
Summary pending - Approved
Pramlintide
Symlin
Amylin analogue
The first amylin analogue, approved by the FDA as an add-on to mealtime insulin in diabetes.
Summary pending - Approved
Secretin
ChiRhoStim
Gut hormone
The first hormone ever described. Approved as a diagnostic agent for pancreatic function.
Summary pending - Approved
Setmelanotide
Imcivree
MC4R agonist
A melanocortin-4 receptor agonist approved for obesity caused by specific rare genetic variants.
Summary pending - Approved
Sincalide
Kinevac
Cholecystokinin fragment
The C-terminal octapeptide of cholecystokinin. Approved as a diagnostic agent for gallbladder imaging.
Summary pending - In trials
Survodutide
BI 456906
GLP-1 and glucagon receptor agonist
A dual agonist in Phase 3 trials for obesity and fatty liver disease.
Summary pending - Approved
Teduglutide
Gattex · Revestive
GLP-2 analogue
A GLP-2 analogue approved for short bowel syndrome.
Summary pending
Immune & airways24
Thymic peptides, antimicrobial peptides and complement inhibitors studied in immune research.
- ResearchAt UU
Thymosin alpha-1
Thymalfasin · Zadaxin
Thymic peptide
A 28-residue thymic peptide registered in a number of countries but not by the FDA or the EMA. Studied as an immune modulator in sepsis and viral infection.
Human trialsShop - ResearchAt UU
Bronchogen
Short bioregulator peptide
A bioregulator peptide associated with bronchial tissue in Russian research. Published evidence is limited.
Summary pendingShop - Approved
Bacitracin
Polypeptide antibiotic
A polypeptide antibiotic best known in topical ointments for minor skin wounds.
Summary pending - In trials
Brilacidin
Defensin mimetic
A synthetic small molecule modelled on host defence peptides. Studied in trials for oral mucositis and infection.
Summary pending - Approved
Colistin
Polymyxin E
Polymyxin antibiotic
A cyclic peptide antibiotic kept as a last-line option for multidrug-resistant Gram-negative infections.
Summary pending - Approved
Cyclosporine
Ciclosporin
Calcineurin inhibitor
A cyclic peptide from a soil fungus. Approved to suppress transplant rejection and for some autoimmune conditions.
Summary pending - Approved
Dalbavancin
Dalvance · Xydalba
Lipoglycopeptide antibiotic
A long-acting lipoglycopeptide antibiotic approved for skin and soft tissue infections.
Summary pending - Approved
Daptomycin
Cubicin
Lipopeptide antibiotic
A cyclic lipopeptide antibiotic approved for serious Gram-positive infections.
Summary pending - Approved
Ecallantide
Kalbitor
Plasma kallikrein inhibitor
A small recombinant protein approved by the FDA for acute attacks of hereditary angioedema.
Summary pending - Approved
Enfuvirtide
Fuzeon
HIV fusion inhibitor
A 36-residue peptide that blocks HIV from fusing with cells. Approved for HIV-1 infection.
Summary pending - Approved
Icatibant
Firazyr
Bradykinin B2 antagonist
A synthetic decapeptide approved for acute attacks of hereditary angioedema.
Summary pending - In trials
LTX-315
Oncopore
Oncolytic peptide
A peptide derived from lactoferricin that disrupts tumour cell membranes. Studied in early cancer immunotherapy trials.
Summary pending - In trials
Nangibotide
TREM-1 inhibitor
A 12-residue peptide that blocks the TREM-1 inflammatory receptor. Studied in clinical trials in septic shock.
Summary pending - Approved
Pegcetacoplan
Empaveli · Aspaveli
Complement C3 inhibitor
A pegylated cyclic peptide that blocks complement C3. Approved for paroxysmal nocturnal haemoglobinuria and geographic atrophy.
Summary pending - Research
Thymulin
Zinc-dependent thymic hormone
A zinc-binding nonapeptide made by the thymus. Studied in animal models of inflammation and pain.
Summary pending - Approved
Vancomycin
Glycopeptide antibiotic
A glycopeptide antibiotic in use since the 1950s, approved for serious Gram-positive infections.
Summary pending - Approved
Zilucoplan
Zilbrysq
Complement C5 inhibitor
A macrocyclic peptide that blocks complement C5. Approved for generalised myasthenia gravis.
Summary pending
Hormones & growth23
Growth hormone secretagogues, IGF analogues and the pituitary and endocrine peptides.
- ResearchAt UU
CJC-1295 with DAC
Long-acting GHRH analogue
A GHRH analogue that binds albumin to stay in circulation for days. Studied in early human trials for sustained IGF-1 elevation.
Early human dataShop - ResearchAt UU
Ipamorelin
Ghrelin receptor agonist
A selective growth hormone secretagogue pentapeptide. Studied for growth hormone release with little effect on cortisol or prolactin.
Early human dataShop - ResearchAt UU
Sermorelin
GRF 1-29
GHRH analogue
The first 29 residues of growth hormone-releasing hormone. Once approved in the US, it was withdrawn from the market in 2008.
Early human dataShop - ResearchAt UU
CJC-1295 without DAC
Modified GRF 1-29 · Mod GRF
GHRH analogue
A stabilised version of the first 29 residues of GHRH. Studied for short pulses of growth hormone release.
Mixed evidenceShop - Approved
Corticotropin
ACTH · Acthar
Pituitary hormone
The 39-residue pituitary hormone that drives cortisol release. Approved for infantile spasms and several inflammatory conditions.
Summary pending - Approved
Cosyntropin
Tetracosactide · Synacthen
ACTH(1-24)
The first 24 residues of ACTH. Approved as a diagnostic test of adrenal function.
Summary pending - Approved
Desmopressin
DDAVP
Vasopressin analogue
A vasopressin analogue that acts on the kidney. Approved for central diabetes insipidus, night-time urination and some bleeding disorders.
Summary pending - Approved
Etelcalcetide
Parsabiv
Calcimimetic
A peptide that activates the calcium-sensing receptor. Approved for secondary hyperparathyroidism on haemodialysis.
Summary pending - Research
Humanin
Mitochondrial-derived peptide
A 24-residue peptide encoded in mitochondrial DNA. Studied in cell and animal models of ageing and neuroprotection.
Summary pending - Research
IGF-1 DES
DES(1-3) IGF-I
IGF-1 variant
A naturally occurring truncated IGF-1 with weak binding-protein affinity. Studied in cell and animal research.
Summary pending - Approved
Insulin analogues
Glargine · Lispro
Insulin
Engineered forms of the 51-residue pancreatic hormone, with faster or longer action. Approved for diabetes.
Summary pending - Approved
Macimorelin
Macrilen
Oral ghrelin receptor agonist
An oral peptidomimetic approved as a diagnostic test for adult growth hormone deficiency.
Summary pending - Approved
Mecasermin
Increlex
Recombinant IGF-1
Recombinant human IGF-1 approved for severe primary IGF-1 deficiency in children.
Summary pending - Research
MK-677
Ibutamoren
Oral ghrelin receptor agonist
An oral small molecule that mimics ghrelin. Studied in trials for growth hormone and IGF-1 levels, never approved.
Summary pending - Approved
Palopegteriparatide
Yorvipath
Long-acting PTH(1-34) prodrug
A prodrug that releases PTH(1-34) steadily. Approved for hypoparathyroidism in adults.
Summary pending - Approved
Pasireotide
Signifor
Somatostatin analogue
A multi-receptor somatostatin analogue approved for Cushing's disease and acromegaly.
Summary pending - Approved
Pegvisomant
Somavert
Growth hormone receptor antagonist
A modified growth hormone that blocks its own receptor. Approved for acromegaly.
Summary pending - Approved
Somapacitan
Sogroya
Long-acting growth hormone
A weekly growth hormone analogue approved for growth hormone deficiency.
Summary pending - Approved
Somatropin
Recombinant human growth hormone
Growth hormone
Recombinant human growth hormone, a 191-residue protein. Approved for growth hormone deficiency and several growth disorders.
Summary pending
Muscle, bone & joint10
Peptides studied for tendon and muscle repair, bone formation and connective tissue.
- Approved
Abaloparatide
Tymlos · Eladynos
PTHrP analogue
An analogue of parathyroid hormone-related protein. Approved for osteoporosis at high risk of fracture.
Summary pending - Approved
Calcitonin (salmon)
Miacalcin
Calcitonin
A 32-residue hormone from salmon, more potent than the human form. Approved for Paget's disease of bone and hypercalcaemia.
Summary pending - Research
Follistatin 344
Myostatin-binding protein
A recombinant form of follistatin, which binds and blocks myostatin. Studied in gene therapy and animal muscle research.
Summary pending - Research
Mechano growth factor
MGF · IGF-1Ec
IGF-1 splice variant peptide
A peptide from the E domain of an IGF-1 splice variant produced in loaded muscle. Studied in cell and animal models.
Summary pending - Approved
Teriparatide
Forteo · Forsteo
PTH(1-34)
The first 34 residues of parathyroid hormone. Approved for osteoporosis at high risk of fracture.
Summary pending - In trials
Thymosin beta-4
RGN-259
Actin-sequestering peptide
The full 43-residue protein that TB-500 is based on. Studied in clinical trials for dry eye and slow-healing wounds.
Summary pending - Approved
Vosoritide
Voxzogo
C-type natriuretic peptide analogue
A CNP analogue that acts on growth plates. Approved to increase linear growth in children with achondroplasia.
Summary pending
Heart & blood10
Vascular peptides, anticoagulants and the mitochondrial peptides studied in cardiac research.
- Approved
Angiotensin II
Giapreza
Vasoconstrictor
A synthetic form of the body's own octapeptide vasoconstrictor. Approved to raise blood pressure in septic and distributive shock.
Summary pending - Approved
Bivalirudin
Angiomax
Direct thrombin inhibitor
A 20-residue synthetic thrombin inhibitor. Approved as an anticoagulant during coronary procedures.
Summary pending - In trials
Enlicitide
MK-0616
Oral macrocyclic PCSK9 inhibitor
An oral macrocyclic peptide that blocks PCSK9. In Phase 3 trials for lowering LDL cholesterol.
Summary pending - Approved
Eptifibatide
Integrilin
Glycoprotein IIb/IIIa inhibitor
A cyclic heptapeptide based on rattlesnake venom. Approved to block platelet clumping in acute coronary syndromes.
Summary pending - Approved
Motixafortide
Aphexda
CXCR4 antagonist
A cyclic peptide that blocks CXCR4. Approved to mobilise stem cells for collection before transplant in multiple myeloma.
Summary pending - Approved
Nesiritide
Natrecor
B-type natriuretic peptide
Recombinant B-type natriuretic peptide, approved by the FDA for acutely decompensated heart failure and now rarely used.
Summary pending - In trials
Rusfertide
Hepcidin mimetic
A synthetic mimic of the iron hormone hepcidin. In Phase 3 trials for polycythaemia vera.
Summary pending - Approved
Terlipressin
Terlivaz
Vasopressin analogue
A vasopressin prodrug approved for hepatorenal syndrome, and in Europe for bleeding oesophageal varices.
Summary pending - Approved
Vasopressin
Vasostrict
Pituitary hormone
The nine-residue antidiuretic hormone. Approved to raise blood pressure in vasodilatory shock.
Summary pending
Sexual & reproductive17
Melanocortins, kisspeptin, oxytocin and the GnRH analogues of reproductive medicine.
- ResearchAt UU
Kisspeptin-10
Kisspeptin receptor agonist
The shortest active fragment of kisspeptin, the upstream signal for GnRH. Studied in human physiology research on reproductive hormones.
Early human dataShop - Approved
Atosiban
Tractocile
Oxytocin receptor antagonist
An oxytocin antagonist approved in Europe to delay imminent preterm birth.
Summary pending - Approved
Cetrorelix
Cetrotide
GnRH antagonist
A GnRH antagonist approved to block premature ovulation during controlled ovarian stimulation in IVF.
Summary pending - Approved
Degarelix
Firmagon
GnRH antagonist
A GnRH antagonist approved for advanced prostate cancer.
Summary pending - Approved
Ganirelix
GnRH antagonist
A GnRH antagonist approved to block the premature LH surge during IVF.
Summary pending - Approved
Gonadorelin
GnRH · Factrel
GnRH
Synthetic gonadotropin-releasing hormone. Approved as a diagnostic agent for pituitary function.
Summary pending - Approved
Goserelin
Zoladex
GnRH agonist
A GnRH agonist given as an implant. Approved for prostate cancer, breast cancer and endometriosis.
Summary pending - Approved
Histrelin
Supprelin LA · Vantas
GnRH agonist
A GnRH agonist given as a yearly implant. Approved for central precocious puberty.
Summary pending - Approved
Human chorionic gonadotropin
hCG · Pregnyl
Glycoprotein hormone
The pregnancy hormone, a glycoprotein that acts at LH receptors. Approved to trigger ovulation and for some forms of hypogonadism.
Summary pending - Approved
Leuprolide
Leuprorelin · Lupron
GnRH agonist
A GnRH agonist approved for prostate cancer, endometriosis and central precocious puberty.
Summary pending - Approved
Nafarelin
Synarel
GnRH agonist
A nasal GnRH agonist approved for endometriosis and central precocious puberty.
Summary pending - Approved
Triptorelin
Trelstar · Decapeptyl
GnRH agonist
A GnRH agonist approved for advanced prostate cancer and, in some markets, other hormone-dependent conditions.
Summary pending
Cells & ageing3
Mitochondrial peptides, telomere research and senescence: the whole-body ageing biology.
The UU library is an educational reference. It is not medical advice, does not make a health claim, and does not tell anyone how to use a compound. UU products are sold for laboratory research use only and are not for human consumption. Regulatory status changes: confirm it with the relevant authority before relying on it.